Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 18.56
- Piotroski Score 2.00
- Grade Buy
- Symbol (DAWN)
- Company Day One Biopharmaceuticals, Inc.
- Price $14.80
- Changes Percentage (1.02%)
- Change $0.15
- Day Low $14.30
- Day High $15.17
- Year High $18.07
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/24/2025
- Fiscal Year End N/A
- Average Stock Price Target $40.00
- High Stock Price Target $45.00
- Low Stock Price Target $24.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.50
- Trailing P/E Ratio -5.11
- Forward P/E Ratio -5.11
- P/E Growth -5.11
- Net Income $-188,917,000
Income Statement
Quarterly
Annual
Latest News of DAWN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Dawn Richard and Spencer Zahn lean into the quiet moments for their new album
Dawn Richard's latest album "Quiet in a World Full of Noise" reflects her journey of vulnerability and self-discovery. She navigates through personal struggles and aims to inspire others to speak thei...
By AP NEWS | 6 days ago -
Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?
The healthcare industry is abuzz with GLP-1 agonists like Ozempic and Wegovy for treating diabetes and obesity. Viking Therapeutics is a key player with potential in the weight loss market, particular...
By Yahoo! Finance | 1 week ago -
Israel attacks Iran in series of pre-dawn airstrikes targeting military infrastructure
Israel conducted pre-dawn airstrikes on Iran in response to ballistic missile attacks. The strikes targeted missile-making facilities and air defense sites, risking escalation. Israel aims to end dire...
By AP NEWS | 1 week ago
